跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
立美芙 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Brodalumab Injection
Approved
生物制品
Brodalumab Injection
KYOWA KIRIN CO., LTD.
🇨🇳 National Medical Products Administration
Approval Date
Jun 17, 2020
Approval ID
7yn0cszc95j
Company
KYOWA KIRIN CO., LTD.
Type
生物制品
Approval Details
Approval Id
7yn0cszc95j
Approval Number
S20200018
Generic Name
布罗利尤单抗注射液
Generic Name En
Brodalumab Injection
Trade Name
立美芙
Drug Type
生物制品
Dosage Form
注射剂
Strength
210mg(1.5ml)/支(预充式注射器)
Reg Date
2020-06-17
Expired Date
2025-06-16
Company Name
KYOWA KIRIN CO., LTD.
Company Address
1-9-2 Otemachi, Chiyoda-ku, Tokyo, Japan
Production Company Name
patheon italia s.p.a., monza operations
Production Company Address
Viale G.B. Stucchi, 110-20900 Monza(MB), Italy
Company Detail Path
/organization/kyowa-kirin-co-ltd
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Jun 17, 2020
Approval ID
7yn0cszc95j
Type
生物制品
Back to NMPA Approvals